Piper Sandler starts AnaptysBio at overweight, cites upcoming readouts
Investing.com | Editor Emilio Ghigini
Published Feb 16, 2024 05:27AM ET
On Friday, Piper Sandler initiated coverage on shares of AnaptysBio (NASDAQ:ANAB), a clinical-stage biotech company, with an Overweight rating and a price target of $80.00. The firm highlighted the company's promising position as it enters a period filled with potential milestones in 2024 and 2025, with four assets in development and two significant partnerships.
AnaptysBio has established a successful track record of advancing molecules from discovery to approval, as demonstrated by their collaboration with GSK. This partnership has resulted in the discovery of the anti-PD-1 antagonist Jemperli, which has been licensed to GSK. Jemperli achieved fiscal year 2023 revenues of £141M, bolstered by its growth as a first-line treatment for endometrial cancer in the United States and its approval in the European Union in December 2023.
Despite these advancements, AnaptysBio's stock is currently trading just over its cash value, with $16 cash per share, and the market has given little recognition to the value of its programs. Piper Sandler believes this presents an opportunity for investors to buy into the stock ahead of key data readouts expected from AnaptysBio's wholly-owned pipeline assets in the next two years.
Moreover, the company is anticipated to benefit from an influx of cash to support its operations through its partnerships, particularly with GSK. This financial backing is seen as an endorsement of AnaptysBio's capabilities and potential for future growth.
Piper Sandler's coverage on AnaptysBio underscores the firm's confidence in the company's prospects, citing the upcoming readouts and indirect catalysts with positive implications as reasons for investors to consider the biotech stock.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Get The News You Want
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.